References
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945–973.e33.
- Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012 Aug;15(8):CD002086.
- Bettoli V, Guerra-Tapia A, Herane MI, et al. Challenges and solutions in oral isotretinoin in acne: reflections on 35 years of experience. Clin Cosmet Investig Dermatol. 2019 Dec;12:943–951.
- Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy. Fourth. Philadelphia: Elsevier; 2020.
- Bremner JD. Isotretinoin and neuropsychiatric side effects: continued vigilance is needed. J Affect Disord Rep. 2021 Dec;6:100230.
- Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Acad Dermatol. 2014 Sep;71(3):450–459.
- Alvarez-Sánchez M, Rodríguez-Ayala E, Ponce-Olivera RM, et al. Bacterial resistance in acne? A meta-analysis of the controversy. Cir Cir Engl Ed. 2016 May;84(3):190–195.
- Acne Medication Market. Global Market Insights; 2020. Report No.: GMI3010.
- Zouboulis CC. Endocrinology and immunology of acne: two sides of the same coin. Exp Dermatol. 2020 Sep;29(9):840–859.
- Montilla CLE, Ball PE, Sáenz AM. PPAR: receptors and agonists. the future of therapy in dermatology? Med Cutan Iber Lat Am. 2019;47(1):16–23.
- Bubna AK. Leukotriene antagonists in dermatology. Indian J Dermatol. 2021 Oct;66(5):575.
- Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019 Sep;14(14):1235–1242.
- Ahirrao P, Shah B, Sumathy T, et al. Efficacy and tolerability of topical fixed combination of nadifloxacin 1% and adapalene 0.1% in the treatment of mild to moderate acne vulgaris in indian patients: a multicenter, open-labelled, prospective study. Indian J Dermatol. 2014;59(4):385.
- Batra R, Sadhasivam S, Saini S, et al. Efficacy and Safety of VB-1953 topical gel in non-responder acne patients with clindamycin-resistant cutibacterium acnes. Drugs RD. 2020 Jun;20(2):95–104.
- Trivedi MK, Bosanac SS, Sivamani RK, et al. Emerging therapies for acne vulgaris. Am J Clin Dermatol. 2018 Aug;19(4):505–516.
- Faccone D, Veliz O, Corso A, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem. 2014 Jan;71:31–35.
- Majeed M, Majeed S, Nagabhushanam K, et al. Novel topical application of a postbiotic, lactosporin®, in mild to moderate acne: a randomized, comparative clinical study to evaluate its efficacy, tolerability and safety. Cosmetics. 2020 Sep 15 7(3):70.
- Elder JT, Fisher GJ, Zhang QY, et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol. 1991 Apr;96(4):425–433.
- Kassir M, Karagaiah P, Sonthalia S, et al. Selective RAR agonists for acne vulgaris: a narrative review. J Cosmet Dermatol. 2020 Jun;19(6):1278–1283.
- Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol [Internet]. 2018 [cited 2022 Jul 4]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bjd.16719
- Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020 Jun 1 156(6):621.
- Zhang L, Li WH, Anthonavage M, et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol. 2011 Jun;660(1):202–206.
- Gupta M. Levamisole: a multi-faceted drug in dermatology. Indian J Dermatol Venereol Leprol. 2016;82(2):230.
- Nature scientific reports has published a peer reviewed paper showing important immune response benefits associated with aobiome’s B244 ammonia oxidizing bacteria drug therapy [Internet]. [cited 2022 Mar 30]. Available from: https://www.prnewswire.com/news-releases/nature-scientific-reports-has-published-a-peer-reviewed-paper-showing-important-immune-response-benefits-associated-with-aobiomes-b244-ammonia-oxidizing-bacteria-drug-therapy-301334632.html
- Maura D, Elmekki N, Goddard CA. The ammonia oxidizing bacterium Nitrosomonas eutropha blocks T helper 2 cell polarization via the anti-inflammatory cytokine IL-10. Sci Rep. 2021 Dec;11(1):14162.
- Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep 2 124(9):3713–3724.
- Yoon JY, Kwon HH, Min SU, et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013 Feb;133(2):429–440.
- Riyanto P, Subchan P, Lelyana R. Advantage of soybean isoflavone as antiandrogen on acne vulgaris. Dermatoendocrinol. 2015 Jan;7(1):e1063751.
- Setchell KDR, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr. 2010 Jul;140(7):1363S–8S.
- Clinical Trials Register [Internet]. [cited 2022 Mar 30]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003307-19/DE
- Picardo M, Cardinali C, La Placa M, et al. Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2022 Jun 23;bjd.21663.
- pharma letter [Internet]. [cited 2022 Mar 30]. Available from: https://www.thepharmaletter.com/article/ct-s-acne-drug-zyflo-fails-in-ph-ii-trial
- Bhatt L, Roinestad K, Van T, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017 Oct;33:65–73.
- Del Rosso JQ, Stein Gold L, Baldwin H, et al. Management of truncal acne with oral sarecycline: pooled results from two phase-3 clinical trials. J Drugs Dermatol JDD. 2021 Jun 1 20(6):634–640.
- ESt O, Mobley WC. Minocycline topical foam: a new drug for the treatment of acne. Ann Pharmacother. 2021 Jan;55(1):105–110.
- Baldwin H, Blanco D, McKeever C, et al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris. J Clin Aesthetic Dermatol. 2016 Aug;9(8):12–18.
- Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002 Feb;69(2 Suppl):12–19.
- Afra TP, Razmi TM, Narang T, et al. Topical tazarotene gel, 0.1%, as a novel treatment approach for atrophic postacne scars: a randomized active-controlled clinical trial. JAMA Facial Plast Surg. 2019 Mar;21(2):125–132.
- Saple DG, Torsekar RG, Pawanarkar V, et al. An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris. Indian J Dermatol Venereol Leprol. 2004 Apr;70(2):92–95.
- Talarozole - adisinsight [Internet]. [cited 2022 Mar 30]. Available from: https://adisinsight.springer.com/drugs/800020802
- Verfaille CJ, Coel M, Boersma IH, et al. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study. Br J Dermatol. 2007 Jul;157(1):122–126.
- Bissonnette R, Poulin Y, Drew J, et al. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: a phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017 Jan;76(1):33–39.
- Dermira’s two phase 3 trials evaluating olumacostat [internet]. [cited 2022 Mar 30]. Available from: https://www.globenewswire.com/news-release/2018/03/05/1414799/0/en/Dermira-s-Two-Phase-3-Trials-Evaluating-Olumacostat-Glasaretil-in-Patients-with-Acne-Vulgaris-Did-Not-Meet-Co-Primary-Endpoints.html
- Melnik BC. Olumacostat glasaretil, a promising topical sebum-suppressing agent that affects all major pathogenic factors of acne vulgaris. J Invest Dermatol. 2017 Jul;137(7):1405–1408.
- Xenon Pharmaceuticals Announces XEN801 Did Not Meet [Internet]. [cited 2022 Mar 30]. Available from: https://www.globenewswire.com/news-release/2017/03/24/943883/0/en/Xenon-Pharmaceuticals-Announces-XEN801-Did-Not-Meet-Efficacy-Endpoints-in-Phase-2-Clinical-Trial-in-Patients-with-Moderate-to-Severe-Acne.html
- Ascletis announces first patient dosed in the phase ii clinical trial of fasn inhibitor asc40 for treatment of moderate to severe acne [Internet]. [cited 2022 Mar 30]. Available from: https://www.prnewswire.com/news-releases/ascletis-announces-first-patient-dosed-in-the-phase-ii-clinical-trial-of-fasn-inhibitor-asc40-for-treatment-of-moderate-to-severe-acne-301460288.html
- A study of a new drug treatment for acne - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01326780
- Rassai S, Mehri M, Yaghoobi R, et al. Superior efficacy of azithromycin and levamisole vs. azithromycin in the treatment of inflammatory acne vulgaris: an investigatorblind randomized clinical trial on 169 patients. Int J Clin Pharmacol Ther. 2013 Jun 1; 51(6):490–494.
- Ansarin H, Savabynasab S, Behzadi AH, et al. Doxycycline plus levamisole: combination treatment for severe nodulocystic acne. J Drugs Dermatol JDD. 2008 Aug;7(8):737–740.
- Carrasco D, Stecher M, Lefebvre GC, et al. Phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity. J Drugs Dermatol JDD. 2015 Jun;14(6):560–564.
- Efficacy and safety study of gevokizumab to treat moderate to severe acne vulgaris - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01498874
- XOMA announces encouraging interim results from gevokizumab phase 2 study for moderate to severe acne vulgaris - aktuell - servier (suisse) S.A. - coversum, Preterax, Fludex,Diamicron, Locabiotal,Arcalion, Daflon [Internet]. [cited 2022 Mar 30]. Available from: https://www.servier.ch/de/aktuell/news-detail/2/xoma-announces-encouraging-interim-results-from-gevokizumab-phase-2-study-for-moderate-to-severe-acne-vulgaris/
- AnaptysisBio Scraps Development of Imsidolimab for Acne After Disappointing Phase 2 Trial | 2022-03-15 | FDAnews [Internet]. [cited 2022 Mar 30]. Available from: https://www.fdanews.com/articles/206995-anaptysisbio-scraps-development-of-imsidolimab-for-acne-after-disappointing-phase-2-trial
- AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical trial of ammonia oxidizing bacteria (aob) for the treatment of acne vulgaris - aobiome [Internet]. [cited 2022 Mar 30]. Available from: https://www.aobiome.com/pressreleases/aobiome-therapeutics-reports-positive-efficacy-results-from-phase-2b-clinical-trial-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-acne-vulgaris/
- clinical trial in subjects with mild to moderate acne vulgaris - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02832063
- Geria AN, Scheinfeld NS. Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Curr Opin Invest Drugs Lond Engl 2000. 2008. Nov;9(11):1228–1237.
- Rudrapal M, Khairnar J, S GJA.Drug repurposing (DR): an emerging approach in drug discovery.F AB,editor.Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications [Internet]. IntechOpen; 2020 [cited 2022 Mar 31]. Available from: https://www.intechopen.com/books/drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications/drug-repurposing-dr-an-emerging-approach-in-drug-discovery
- Bassi A, Arfin S, Joshi R, et al. Challenges in operationalising clinical trials in India during the COVID-19 pandemic. Lancet Glob Health. 2022 Mar;10(3):e317–9.